← All indications
Myocardial Ischemia
A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
Subtype terms (6)
More specific conditions that are subtypes of Myocardial Ischemia in the MeSH hierarchy.
- Acute Coronary Syndrome
161 drugs (107 approved, 54 experimental)
- Angina Pectoris
119 drugs (61 approved, 58 experimental)
- Coronary Disease
278 drugs (174 approved, 104 experimental)
- Kounis Syndrome
- Myocardial Infarction
336 drugs (202 approved, 134 experimental)
- Myocardial Reperfusion Injury
28 drugs (22 approved, 6 experimental)
Drugs by status
Approved for this indication (4)
Phase 4 trials (52)
- ringer's lactate
- edoxaban
- allopurinol
- heparin
- oxytocin
- acetylcysteine
- dabigatran
- umirolimus
- carbetocin
- esmolol
- ibuprofen
- escitalopram
- l-glutamine
- amlodipine
- ivabradine
- adenosine
- icosapent ethyl
- atorvastatin
- ticagrelor
- valsartan
- prasugrel
- pravastatin
- ranolazine
- dipyridamole
- sitagliptin
- levobupivacaine
- celecoxib
- acetylsalicylic acid
- sorbitol
- everolimus
- +22 more
Phase 3 trials (61)
- simvastatin
- vitamin d3
- nitroglycerin
- vitamin e
- apadenoson
- chlorthalidone
- cholestyramine
- clofibrate
- colestipol
- atenolol
- conjugated equine estrogens
- prednisone
- progesterone
- diltiazem
- nifedipine
- enalapril
- paclitaxel
- naltrexone
- calcium
- rosuvastatin
- warfarin
- bovine colostrum
- autologous cd133+ stem cells
- eptifibatide
- soybean oil
- ozone
- magnesium oxide
- iohexol
- irbesartan
- moricizine
- +31 more
Phase 2 trials (49)
- melatonin
- sodium nitrite
- omecamtiv mecarbil
- ad-hgf
- beta carotene
- dutogliptin
- eleclazine
- fgf-1
- flurpiridaz
- folic acid
- gadofosveset trisodium
- gemfibrozil
- somatropin
- hemin
- bone marrow derived mesenchymal stem cells
- cyanocobalamin
- Filgrastim
- tryptophan
- rimabotulinumtoxinB
- nitric oxide
- peripheral blood lymphocytes
- lactose
- colchicine
- pz-128
- aliskiren
- stem cells
- tp10
- umbilical cord mesenchymal stem cells
- autologous bone marrow derived mesenchymal cells
- cold blood
- +19 more
Phase 1 trials (8)
Other trials (29)
- propofol
- perfluorobutane
- aprotinin
- candesartan
- d-ribose
- empagliflozin
- gadobutrol
- isoflurane
- sevoflurane
- ethinyl estradiol
- abciximab
- acetylcholine chloride
- Molsidomine
- technetium tc-99m sestamibi
- sufentanil
- vardenafil
- thiamine
- creatine
- losartan
- metoprolol
- bivalirudin
- hydrochlorothiazide
- telmisartan
- bisoprolol
- rubidium chloride rb-82
- lycopene
- mavacamten
- arginine
- norethindrone
Organizations
Organization Involved with Phase 4 Indications (246)
- Clinical Hospital Center Zemun
- Daewoong Pharmaceutical Co. LTD.
- Icahn School of Medicine at Mount Sinai
- Sanofi
- University of Sao Paulo
- China Medical University
- Dammam Central Hospital
- New York University
- University of Florida
- Hospital Alessandro Manzoni Lecco
- Samjin Pharmaceutical Co., Ltd.
- General Electric
- British Heart Foundation
- Shanghai MicroPort Medical (Group) Co., Ltd.
- Central South University
- I.M. Sechenov First Moscow State Medical University
- Ural Institute of Cardiology
- National Institute of General Medical Sciences (NIGMS)
- Ural State Medical Academy
- National Health and Medical Research Council, Australia
- Harbin Medical University
- Eli Lilly
- Lantheus Medical Imaging
- Ankara Yildirim Beyazıt University
- Rapid City Regional Hospital
- ANKON Medical Technologies
- Novartis
- Methodist Cancer Center, Houston, Texas
- Korea University
- Kumamoto University
- +216 more
Organization Involved with Phase 3 Indications (187)
- Kastle Therapeutics, LLC
- University of California, San Diego
- Boston University
- Institute of Cardiology, Warsaw, Poland
- Los Angeles Biomedical Research Institute
- New England Research Institutes
- Yale University
- Hospital do Coracao
- Dong-A University
- Resverlogix Corp
- Gachon University
- Columbia University
- Atlantic Health System
- Erasmus University Rotterdam
- University of Minnesota
- Anesiva, Inc.
- Henry Ford Health System
- Boston Health and Hospitals Department
- University of Gothenburg
- Tufts University
- University Hospital of North Norway
- Maryland Medical Research Institute
- Advanced Biosciences Research
- German Heart Institute
- Anthropometrics Heart Clinic
- Government of Norway
- Shahid Beheshti University of Medical Sciences
- Linkoping University
- Bio-Science Laboratories
- Danish Heart Foundation
- +157 more
Organization Involved with Phase 2 Indications (96)
- Kent Hospital, Rhode Island
- XyloCor Therapeutics, Inc.
- Sarepta Therapeutics
- University of Naples Frederico II
- Centre for Digestive Diseases, Australia
- Dicofarm
- Eisai
- University of Helsinki
- Platelet and Thrombosis Research L.L.C
- Oakland University
- Xijing Hospital
- Government of France
- Venturis Therapeutics
- Government of Poland
- University Alicante
- Fundacion Investigacion y Desarrollo
- German Center for Cardiovascular Research e. V. (DZHK)
- TCA Cellular Therapy
- Rawalpindi Institute of Cardiology
- The Medicines Company
- University of Tennessee
- Guang Anmen Hospital
- University of Grenoble
- FluoroPharma, Inc.
- University of Toulouse
- Barts & The London NHS Trust
- Ono Pharmaceuticals
- Ivy Institute of Stem Cells Co. Ltd
- CV Therapeutics
- Georgetown University
- +66 more
Organization Involved with Phase 1 Indications (19)
- Lee's Pharmaceutical
- Kuopio University Hospital
- RegeneRx Biopharmaceuticals, Inc.
- Canadian Institutes of Health Research (CIHR)
- AlphaCore Pharma LLC
- Masih Daneshvari Hospital
- Karolinska Institute
- Thoratec
- Healthcare Discoveries Inc.
- Cytori Therapeutics
- Honya Medical Inc
- University of Kentucky
- Asklepion
- University of Eastern Finland
- Liuhuaqiao Hospital
- Vanderbilt University
- McGill University
- Chang Gung University
- University of Louisville
Organization Involved with Other Experimental Indications (68)
- Henan Institute of Cardiovascular Epidemiology
- University of Tokyo
- Bassett Healthcare
- St. John's Research Institute
- Allegiance Health
- McMaster University
- Fujian Medical University
- Julius-Maximilians University
- Tohoku University
- Reliant Pharmaceuticals
- Creighton University
- Triemli Hospital
- University of Connecticut
- American Egg Board
- Fosun
- Luzerner Kantonsspital
- Abderrahmane Mami Hospital
- Sun Yat-Sen University
- Hospital Lucerne
- Medical Research Foundation, Oregon
- Shengjing Hospital
- Nanjing University
- University of Freiburg
- New York City Health and Hospitals Corporation
- Shantou University
- Free University of Brussels
- Guangzhou University of Chinese Medicine
- Konkuk University
- Oregon Health and Science University
- University of Lausanne
- +38 more